Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2012

01.02.2012 | Epidemiology

Prognostic role of CA15.3 in 7942 patients with operable breast cancer

verfasst von: M. T. Sandri, M. Salvatici, E. Botteri, R. Passerini, L. Zorzino, N. Rotmensz, A. Luini, C. Mauro, V. Bagnardi, M. C. Cassatella, F. Bottari, C. Casadio, M. Colleoni

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

To assess the prognostic value of presurgical CA15.3 in a large cohort of patients with early breast cancer. A total of 7.942 consecutive patients with breast cancer operated at the European Institute of Oncology between 1998 and 2005 and with presurgical values of CA 15.3 available were included. We explored patterns of recurrence by baseline CA 15.3 values. Mean CA15.3 was 17.0 U/ml. CA15.3 was associated with age, tumor size, nodal involvement, Ki-67 labeling index, grade, HER2 expression, molecular subtype, and perivascular invasion. CA15.3 was independently associated with distant metastases [HR > 20 U/ml vs. ≤ 20 U/ml: 1.34 (95% CI 1.15–1.56)] and death [HR > 20 U/ml vs. ≤ 20 U/ml: 1.30 (95% CI 1.11–1.53)]. When considering CA15.3 as continuous variable, we observed a constant risk of metastasis and death from the lowest values to about 15–20 U/ml, and then a significantly increasing risk with increasing values of CA15.3. Finally, CA15.3 provided significant additional information to the common prognostic factors to predict the occurrence of metastases (C-index P value 0.04). In patients with operable breast cancer, presurgical CA15.3 value is an independent prognostic factor for metastases and deaths. CA15.3 provides additional information to the common prognostic factors and should be considered in the adjuvant therapeutic algorithm.
Literatur
1.
Zurück zum Zitat Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151–1159PubMed Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151–1159PubMed
2.
Zurück zum Zitat Hilkens J, Buijs F, Hilgers J et al (1984) Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of mammary gland and its tumor. Int J Cancer 34:197–206PubMedCrossRef Hilkens J, Buijs F, Hilgers J et al (1984) Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of mammary gland and its tumor. Int J Cancer 34:197–206PubMedCrossRef
3.
Zurück zum Zitat Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane associated mucin episialian/MUC1. Mol Biol Cell 7:565–577PubMed Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane associated mucin episialian/MUC1. Mol Biol Cell 7:565–577PubMed
4.
Zurück zum Zitat Fung PYS, Longenecker BM (1991) Specific immunosuppressive activity of epiglycanin, a mucin like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 51:1170–1176PubMed Fung PYS, Longenecker BM (1991) Specific immunosuppressive activity of epiglycanin, a mucin like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 51:1170–1176PubMed
5.
Zurück zum Zitat Gimmi CD, Morrison BW, Mainprice BA et al (1996) Breast cancer associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2:1369–1370CrossRef Gimmi CD, Morrison BW, Mainprice BA et al (1996) Breast cancer associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2:1369–1370CrossRef
6.
Zurück zum Zitat Agrawal B, Gendler SJ, Longenecker BM (1998) The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 4:397–403PubMedCrossRef Agrawal B, Gendler SJ, Longenecker BM (1998) The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 4:397–403PubMedCrossRef
7.
Zurück zum Zitat Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC (2010) MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 201:102–110PubMedCrossRef Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC (2010) MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 201:102–110PubMedCrossRef
8.
Zurück zum Zitat Duffy MJ (1999) CA 15–3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 36:579–586PubMed Duffy MJ (1999) CA 15–3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 36:579–586PubMed
9.
Zurück zum Zitat Duffy MJ, Shering S, Sherry F et al (2000) CA 15–3: a prognostic marker in breast cancer. Int J Biol Markers 15:330–333PubMed Duffy MJ, Shering S, Sherry F et al (2000) CA 15–3: a prognostic marker in breast cancer. Int J Biol Markers 15:330–333PubMed
10.
Zurück zum Zitat Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMedCrossRef Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMedCrossRef
11.
Zurück zum Zitat McLaughlin R, McGrath J, Grimes, Given HF (2000) The prognostic value of the tumor marker CA 15–3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 15:340–342PubMed McLaughlin R, McGrath J, Grimes, Given HF (2000) The prognostic value of the tumor marker CA 15–3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 15:340–342PubMed
12.
Zurück zum Zitat Canizares F, Sola J, Perez M et al (2001) Preoperative values of CA15.3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumor Biol 22:273–281CrossRef Canizares F, Sola J, Perez M et al (2001) Preoperative values of CA15.3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumor Biol 22:273–281CrossRef
13.
Zurück zum Zitat Gion M, Boracchi P, Dittardi R et al (2002) Prognostic role of serum CA 15-3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38:1181–1188PubMedCrossRef Gion M, Boracchi P, Dittardi R et al (2002) Prognostic role of serum CA 15-3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38:1181–1188PubMedCrossRef
14.
Zurück zum Zitat Ebeling FG, Stieber P, Untch M et al (2002) Serum CEA and CA 15–3 as a prognostic factors in primary breast cancer. Br J Cancer 86:1217–1222PubMedCrossRef Ebeling FG, Stieber P, Untch M et al (2002) Serum CEA and CA 15–3 as a prognostic factors in primary breast cancer. Br J Cancer 86:1217–1222PubMedCrossRef
15.
Zurück zum Zitat Kumpulainen EJ, Keskikuru RJ, Johansson RT (2002) Serum tumor marker CA 15–3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 76:95–102PubMedCrossRef Kumpulainen EJ, Keskikuru RJ, Johansson RT (2002) Serum tumor marker CA 15–3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 76:95–102PubMedCrossRef
16.
Zurück zum Zitat Molina R, Filella X, Alicarte J et al (2003) Prospective evaluation of CEA and CA15.3 in patients with locoregionale breast cancer. Anticancer Res 23:1035–1042PubMed Molina R, Filella X, Alicarte J et al (2003) Prospective evaluation of CEA and CA15.3 in patients with locoregionale breast cancer. Anticancer Res 23:1035–1042PubMed
17.
Zurück zum Zitat Duffy MJ, Duggan C, Keane R et al (2004) High preoperative CA 15–3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 50:559–563PubMedCrossRef Duffy MJ, Duggan C, Keane R et al (2004) High preoperative CA 15–3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 50:559–563PubMedCrossRef
18.
Zurück zum Zitat Martin A, Corte MD, Alvarez AM et al (2006) Prognostic value of pre-operative serum CA15.3 levels in breast cancer. Anticancer Res 26:3965–3972PubMed Martin A, Corte MD, Alvarez AM et al (2006) Prognostic value of pre-operative serum CA15.3 levels in breast cancer. Anticancer Res 26:3965–3972PubMed
19.
Zurück zum Zitat Velaiutham S, Taib NA, Ng KL, Yoong BK, Yip CH (2008) Does the pre-operative value of serum CA15.3 correlate with survival in breast cancer? Asian Pac J Cancer Prev 9:445–448PubMed Velaiutham S, Taib NA, Ng KL, Yoong BK, Yip CH (2008) Does the pre-operative value of serum CA15.3 correlate with survival in breast cancer? Asian Pac J Cancer Prev 9:445–448PubMed
20.
Zurück zum Zitat Park BW, Oh JW, Kim JH et al (2008) Preoperative CA 15–3 and CEA serum levels as predictor for breast cancer outcomes. Ann of Oncol 19:675–681CrossRef Park BW, Oh JW, Kim JH et al (2008) Preoperative CA 15–3 and CEA serum levels as predictor for breast cancer outcomes. Ann of Oncol 19:675–681CrossRef
21.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747PubMedCrossRef Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747PubMedCrossRef
22.
Zurück zum Zitat Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedCrossRef Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedCrossRef
23.
Zurück zum Zitat Viale G, Regan MM, Maiorano E et al (2007) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. J Clin Oncol 25:3846–3852PubMedCrossRef Viale G, Regan MM, Maiorano E et al (2007) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. J Clin Oncol 25:3846–3852PubMedCrossRef
24.
Zurück zum Zitat Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569–5575PubMedCrossRef Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569–5575PubMedCrossRef
25.
Zurück zum Zitat Rasmussen BB, Regan MM, Lykkesfeldt AE et al (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. Lancet Oncol 9:23–28PubMedCrossRef Rasmussen BB, Regan MM, Lykkesfeldt AE et al (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. Lancet Oncol 9:23–28PubMedCrossRef
26.
Zurück zum Zitat Gray RJ (1998) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 16:1141–1154CrossRef Gray RJ (1998) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 16:1141–1154CrossRef
27.
Zurück zum Zitat Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551–561PubMedCrossRef Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551–561PubMedCrossRef
28.
Zurück zum Zitat Antolini L, Nam B-H, D’Agostino RB (2004) Inference on correlated discrimination measures in survival analysis: a nonparametric approach. Comm Statist Theory Methods 33:2117–2135CrossRef Antolini L, Nam B-H, D’Agostino RB (2004) Inference on correlated discrimination measures in survival analysis: a nonparametric approach. Comm Statist Theory Methods 33:2117–2135CrossRef
29.
Zurück zum Zitat Davis BW, Gelber RD, Goldhirsch A et al (1986) Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58:2662–2670PubMedCrossRef Davis BW, Gelber RD, Goldhirsch A et al (1986) Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58:2662–2670PubMedCrossRef
30.
Zurück zum Zitat Layfield LJ, Goldstein N, Perkinson KR, Proia AD (2003) Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J 9:257–259PubMedCrossRef Layfield LJ, Goldstein N, Perkinson KR, Proia AD (2003) Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J 9:257–259PubMedCrossRef
31.
Zurück zum Zitat Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10–19PubMedCrossRef Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10–19PubMedCrossRef
32.
Zurück zum Zitat Perez EA, Suman VJ, Davidson NE et al (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032–3038PubMedCrossRef Perez EA, Suman VJ, Davidson NE et al (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032–3038PubMedCrossRef
33.
Zurück zum Zitat Mukhopadhyay P, Chakraborty S, Ponnusamy MP et al (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 1815:224–240PubMed Mukhopadhyay P, Chakraborty S, Ponnusamy MP et al (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 1815:224–240PubMed
34.
Zurück zum Zitat Perou C, Sorlie T, Elsen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef Perou C, Sorlie T, Elsen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef
35.
Zurück zum Zitat Sorlie T, Perou AM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef Sorlie T, Perou AM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef
36.
Zurück zum Zitat Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800PubMedCrossRef Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800PubMedCrossRef
37.
Zurück zum Zitat Viale G, Rotmensz N, Maisonneuve P et al (2009) Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116:317–328PubMedCrossRef Viale G, Rotmensz N, Maisonneuve P et al (2009) Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116:317–328PubMedCrossRef
Metadaten
Titel
Prognostic role of CA15.3 in 7942 patients with operable breast cancer
verfasst von
M. T. Sandri
M. Salvatici
E. Botteri
R. Passerini
L. Zorzino
N. Rotmensz
A. Luini
C. Mauro
V. Bagnardi
M. C. Cassatella
F. Bottari
C. Casadio
M. Colleoni
Publikationsdatum
01.02.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1863-x

Weitere Artikel der Ausgabe 1/2012

Breast Cancer Research and Treatment 1/2012 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.